# Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

> **NCT06301828** · PHASE2 · UNKNOWN · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 16 (estimated)

## Conditions studied

- Gastrointestinal Neoplasms

## Interventions

- **DRUG:** Envafolimab Injection
- **DRUG:** Endostar

## Key facts

- **NCT ID:** NCT06301828
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-21
- **Primary completion:** 2025-06-21
- **Final completion:** 2026-02-21
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06301828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06301828, "Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06301828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*